Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models

Toxicology Mechanisms and Methods

Volumn 18, Issue 2-3, 2008, Pages 217-227

  Kruhlak, Naomi L ^a   Choi, Sydney S ^a   Contrera, Joseph F ^a,c   Weaver, James L ^a   Willard, James M ^a   Hastings, Kenneth L ^a,b   Sancilio, Lawrence F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Sanofi Aventis Inc   (United States)

^c Computational Toxicology Services LLC ^*  (United States)

Author keywords

Computational Toxicology; Consensus Predictions; Cross Validation; Database; In Silico Modeling; MC4PC; MDL QSAR; Phospholipidosis; QSAR

Indexed keywords

AMITRIPTYLINE; AZACOSTEROL; CITALOPRAM; CLINDAMYCIN;

ARTICLE; CHEMICAL STRUCTURE; CLINICAL STUDY; COMPUTER MODEL; COMPUTER PROGRAM; CORRELATION ANALYSIS; DATA BASE; ELECTRON MICROSCOPY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTHESIS; LIPIDOSIS; LYSOSOME; MEDICAL LITERATURE; MOLECULAR MODEL; NONHUMAN; PREDICTIVE VALIDITY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SENSITIVITY AND SPECIFICITY; TRAINING; VALIDATION PROCESS;

ANIMALIA;

EID: 40949111469     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376510701857262     Document Type: Article

References (57)

1. Anderson, N., and Borlak, J. 2006. Drug-induced phospholipidosis. FEBS Lett. 580:5533-5540.
2. Anderson, T.W. 1984. An Introduction to Multivariate Statistical Analysis, Second Edition, John Wiley and Sons, Inc., New York.
3. Bailey, A. B., Chanderbhan, R., Collazo-Braier, N., Cheeseman, M. A., and Twaroski, M. L. 2005. The use of structure-activity relationship analysis in the food contact notification program. Regul. Toxicol. Pharmacol. 42:225-235.
4. Bandyopadhyay, S., Klaunig, J. E., and Somani, P. 1990. Cytotoxic interactions of cardioactive cationic amphiphilic compounds in primary rat hepatocytes in culture. Hepatology 12:48-58.
5. Baronas, E. T., Lee, J. W., Alden, C., and Hsieh, F. Y. 2007. Biomarkers to monitor drug-induced phospholipidosis. Toxicol. Appl. Pharmacol. 218:72-78.
6. Barone, L., Small, B. G., Valentin, J., Pollard, C. E., and Ciaccio, P. J. 2007. A comparison between compound potency in an in vitro phospholipidosis assay and at the hERG-encoded potassium channel, Poster. Society of Toxicology Meeting, Charlotte, NC.
7. Brown, W. J., Sullivan, T. R., and Greenspan, P. 1992. Histochem. 97:349-354.
8. Contrera, J. F., Hall, L. H., Kier, L. B., and MacLaughlin, P. 2005a. QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors. Curr. Drug Discov. Technol. 2:55-67.
9. Contrera, J. F., Kruhlak, N. L., Matthews, E. J., and Benz, R. D. 2005b. In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software. Regul. Toxicol. Pharmacol. 43:313-323.
10. Contrera, J. F., Kruhlak, N. L., Matthews, E. J., and Benz, R. D. 2007. Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. Regul. Toxicol. Pharmacol. 49:172-182.
11. Contrera, J. F., Matthews, E. J., and Benz, R. D. 2003. Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. Regul. Toxicol. Pharmacol. 38:243-259.
12. Cooper, J. A., Saracci, R., and Cole, P. 1979. Describing the validity of carcinogen screening tests. Br. J. Cancer 39:87-89.
13. Delaney, J., Neville, W. A., Swain, A., Miles, A., Leonard, M. S., and Waterfield, C. J. 2004. Phenylacetylglicine, a putative biomarker of phospholipidosis: its origins and relevance to phospholipid accumulation using amiodarone treated rats as amodel. Biomarkers 9:271-290.
14. Dieterle, F., Ross, A., Schlotterbeck, G., and Senn, H. 2006. Metabolite projection analysis for fast identification of metabolites in metabonomics. Application in an amiodarone study. Anal. Chem. 78:3551-3561.
15. Grabner, R. 1987. Influence of cationic amphiphilic drugs on the phosphatidylcholine hydrolysis by phospholipase A2. Biochem. Pharmacol. 36:1063-1067.
16. Greene, N. 2002. Computer systems for the prediction of toxicity: an update. Adv. Drug Deliv. Rev. 54:417-431.
17. Gum, R. J., Hickman, D., Fagerland, J. A., Heindel, M. A., Gagne, G. D., Schmidt, J. M., Michaelides, M. R., Davidsen, S. K., and Ulrich, R. G. 2001. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem. Pharmacol. 62:1661-1673.
18. Hall, L. H. 2004. A structure-information approach to prediction of biological activities and properties. Chem. Biodiversity 1:183-201.
19. Hall, L. H., and Kier, L. B. 1995. Electrotopological state indices for atom types: a novel combination of electronic, topological and valence state information. J. Chem. Inf. Comput. Sci. 35:1039-1045.
20. Hall, L. H., and Kier, L. B. 1999. Molecular connectivity indices for database analysis and structure-property modeling. In: Devillers, P., and Balaban, A. T. (Eds.), Topological Indices and Related Descriptors in QSAR and QSPR, Gordon and Breach Science Publishers, The Netherlands, pp. 307-360.
21. Hall, L. H., and Kier, L. B. 2001. Issues in the representation of molecular structure: the development of molecular connectivity. J. Molec. Graph. Model 20:4-18.
22. Halliwell, W. H. 1997. Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 25:53-60.
23. Hruban, Z. 1984. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ. Health Perspect. 55:53-76.
24. Ibrahim, S., Langhendries, J. P., Bernard, A., and Tulkens, P. M. 1994. Urinary phospholipids excretion in neonates treated with amikacin. Int. J. Clin. Pharm. Res. 14:149-156.
25. Johnson, D. E., and Rodgers, A. D. 2006. Computational toxicology: heading towardmore relevance in drug discovery and development. Curr. Opin. Drug Discov. Devel. 9:29-37.
26. Kendall, M. G., Stuart, A., and Ord, J. K. 1983. The Advanced Theory of Statistics, Vol. 3, Fourth Edition, Macmillan Publishing Co., Inc., New York.
27. Kodavanti, U. P., and Mehendale, H. M. 1990. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol. Rev. 42:327-354.
28. Kruhlak, N. L., Contrera, J. F., Benz, R. D., and Matthews, E. J. 2007. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. Adv. Drug Deliv. Rev. 59:43-55.
29. 1. Biochemistry 24:6515-6520.
30. 1 in liver - a brief survey. Klin. Wochenschr. 67:126-130.
31. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26.
32. Lüllmann, H., Lüllmann-Rauch, R., and Wassermann, O. 1978. Lipidosis induced by amphiphilic cationic drugs. Biochem. Pharmacol. 27:1103-1108.
33. Matthews, E. J., and Contrera, J. F. 1998. A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. Regul. Toxicol. Pharmacol. 28:242-264.
34. Matthews, E. J., Kruhlak, N. L., Benz, R. D., and Contrera, J. F. 2004. Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. Curr. Drug Discov. Technol. 1:61-76.
35. Matthews, E. J., Kruhlak, N. L., Benz, R. D., Ivanov, J., Klopman, G., and Contrera, J. F. 2007. A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicals. Regul. Toxicol. Pharmacol. 47:136-155.
36. Matthews, E. J., Kruhlak, N. L., Cimino, M. C., Benz, R. D., and Contrera, J. F. 2006. Analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. Regul. Toxicol. Pharmacol. 44:97-110.
37. Morelli, J. K., Buehrle, M., Pognan, F., Barone, L. R., Fieles, W., and Ciaccio, P. J. 2006. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol. Toxicol. 22:15-27.
38. Mortuza, G. B., Nebille, W. A., Delaney, J., Waterfield, C. J., and Camilleri, P. 2003. Characterization of a potential biomarker of phospholipidosis from amiodarone-treated rats. Biochim. Biophys. Acta 1631:136-146.
39. Nassogne, M. C., Lizarraga, C., N'Kuli, F., Van Bambeke, F., Van Binst, R., Wallemacq, P., Tulkens, P. M., Mingeot-Leclercq, M. P., Levade, T., and Courtoy, P. J. 2004. Cocaine induces amixed lysosomal lipidosis in cultured fibroblasts, by inactivation of acid sphingomyelinase and inhibition of phospholipase A1. Toxicol. Appl. Pharmacol. 194:101-110.
40. National Library of Medicine. 2007. ChemIDplus Advanced. Online database. http://chem.sis.nlm.nih.gov/chemidplus/. Accessed July 2007.
41. Nelson, A. A., and Fitzhugh, O. G. 1948. Chloroquine (SN-7618). Pathological changes observed in rats which for two years had been fed various proportions. Arch. Pathol. 45:454-462.
42. Organisation for Economic Cooperation and Development (OECD). 2004. The report from the expert group on (quantitative) structure-activity relationships [(Q)SARs] on the principles for the validation of (Q)SARs. No. 49. ENV/JM/MONO(2004)24. Organisation for Economic Cooperation and Development, Paris.
43. Pelletier, D. J., Gehlhaar, D., Tilloy-Ellul, A., Johnson, T. O., and Greene, N. 2007. Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. J. Chem. Inf. Model. 47:1196-1205.
44. Ploemen, J. P., Kelder, J., Hafmans, T., van de Sandt, H., van Burgsteden, J. A., Saleminki, P. J., and van Esch, E. 2004. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis inducing potential: a case study with structurally related piperazines. Exp. Toxicol. Pathol. 55:347-355.
45. Reasor, M. J., Hastings, K. L., and Ulrich, R. G. 2006. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf. 5:567-583.
46. Reasor, M. J., Heyneman, C. A., and Walker, E. R. 1982. Chlorcyclizine-induced pulmonary phospholipidosis in rats. Res. Comm. Chem. Pathol. Pharmacol. 38:235-246.
47. Richard, A. M., Gold, L. S., and Nicklaus, M. C. 2006. Chemical structure indexing of toxicity data on the internet: moving toward a flat world. Curr. Opin. Drug Discov. Devel. 9:314-325.
48. Sawada, H., Takami, K., and Asahi, S. A. 2005. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 83:282-292.
49. Seydel, J. K., and Wassermann, O. 1976. NMR-studies on the molecular basis of drug-induced phospholipidosis - II. Interaction between several amphiphilic drugs and phospholipids. Biochem. Pharmacol. 25:2357-2364.
50. Six, D. A., and Dennis, E. A. 2000. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochem. Biophys. Acta. 1488:1-19.
51. Tomizawa, K., Sugano, K., Yamada, H., and Horii, I. 2006. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. J. Toxicol. Sci. 31:315-324.
52. U.S. Food and Drug Administration. 2004. Challenge and opportunity on the critical path to new medical products. White paper. http://www.fda.gov/oc/ initiatives/criticalpath/whitepaper.html. Accessed July 2007.
53. Wagner, P. M., Nabholz, J. V., and Kent, R. J. 1995. The new chemicals process at the Environmental Protection Agency (EPA): structure-activity relationships for hazard identification and risk assessment. Toxicol. Lett. 79:67-73.
54. Wang, X., Phelan, S. A., Forsman-Semb, K., Taylor, E. F., Petros, C., Brown, A., Lerner, C. P., and Paigen, B. 2003. Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J. Biol. Chem. 278:25179-25190.
55. Waring, J. F., Cavet, G., Jolly, R. A., McDowell, J., Dai, H., Ciurlionis, R., Zhang, C., Stoughton, R., Lum, P., Ferguson, A., Roberts, C. J., and Ulrich, R. G. 2003. Development of a DNA microarray for toxicology based on hepatotoxin-regulated sequences. Environ. Health Perspect. Toxicogenomics 111:53-60.
56. Yang, C., Benz, R. D., and Cheeseman, M. A. 2006. Landscape of current toxicity databases and database standards. Curr. Opin. Drug Discov. Devel. 9:124-133.
57. Zeeman, M., Auer, C. M., Clements, R. G., Nabholz, J. V., and Boethling, R. S. 1995. U.S. EPA regulatory perspectives on the use of (Q)SAR for new and existing chemical evaluations. SAR QSAR Environ. Res. 3:179-201.